Reconstitution of Natural Killer Cells in HLA-Matched HSCTafter Reduced-Intensity Conditioning: Impact on ClinicalOutcome

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 3, 2015, Pages 429-439

  Pical Izard, Caroline ^a   Crocchiolo, Roberto ^b,c   Granjeaud, Samuel ^a   Kochbati, Eloise ^a   Just Landi, Sylvaine ^a   Chabannon, Christian ^a,b,d   Frassati, Coralie ^e   Picard, Christophe ^e   Blaise, Didier ^a,c   Olive, Daniel ^a   Fauriat, Cyril ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d INSERM   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

HLA matched; NK cells; NK functions; Reduced intensity conditioning; Stem cell transplantation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CYTOKINE PRODUCTION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENOTYPE; HLA MATCHING; HUMAN; INCIDENCE; INFECTION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; TARGET CELL; UNRELATED DONORS; ADULT; AGED; ALLOGRAFT; CLINICAL TRIAL; CONVALESCENCE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; ALLOGRAFTS; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

EID: 84922808427     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.11.681     Document Type: Article

References (37)

1. Björkström N.K., Riese P., Heuts F., et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010, 116:3853-3864.
2. Miller J.S., Warren E.H., van den Brink M.R.M., et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010, 16:565-586.
3. Foley B., Cooley S., Verneris M.R., et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119:2665-2674.
4. Yawata M., Yawata N., Draghi M., et al. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK cell repertoires towards a balance of missing-self response. Blood 2008, 112:2369-2380.
5. Fauriat C., Andersson S., Björklund A.T., et al. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. JImmunol 2008, 181:6010-6019.
6. Béziat V., Dalgard O., Asselah T., et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 2011, 42:447-457.
7. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
8. Lopez-Verges S., Milush J.M., Schwartz B.S., et al. Expansion of a unique CD57[U+207A]NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011, 108:14725-14732.
9. Sun J.C., Madera S., Bezman N.A., et al. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. JExp Med 2012, 209:947-954.
10. Bryceson Y.T., Fauriat C., Nunes J.M., et al. Functional analysis of human NK Cells by flow cytometry 2010, Humana Press, Totowa, NJ.
11. Beziat V., Duffy D., Quoc S.N., et al. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. JImmunol 2011, 186:6753-6761.
12. Yu J., Venstrom J.M., Liu X.R., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009, 113:3875-3884.
13. Lopez-Verges S., Milush J.M., Pandey S., et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010, 116:3865-3874.
14. Moretta L. Dissecting CD56dim human NK cells. Blood 2010, 116:3689-3691.
15. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
16. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
17. Tsirigotis P.D., Resnick I.B., Shapira M.Y. The role of natural killer cells in hematopoietic stem cell transplantation. Ann Med 2012, 44:130-145.
18. Foley B., Cooley S., Verneris M.R., et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011, 118:2784-2792.
19. Andersson S., Fauriat C., Malmberg J.-A., et al. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009, 114:95-104.
20. Fauriat C., Long E.O., Ljunggren H.-G., Bryceson Y.T. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2176.
21. Björklund A.T., Schaffer M., Fauriat C., et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010, 115:2686-2694.
22. De Maria A., Bozzano F., Cantoni C., Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011, 108:728-732.
23. Haas P., Loiseau P., Tamouza R., et al. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood 2011, 117:1021-1029.
24. Roederer M., Nozzi J.L., Nason M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011, 79:167-174.
25. Wang H., Grzywacz B., Sukovich D., et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007, 110:1530-1539.
26. Veuillen C., Aurran-Schleinitz T., Castellano R., et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome invitro and invivo by priming NK cells and monoclonal antibody therapy. JClin Immunol 2012, 32:632-646.
27. Cooper M.A., Fehniger T.A., Turner S.C., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151.
28. Béziat V., Liu L.L., Malmberg J.-A., et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013, 121:2678-2688.
29. Schonberg K., Sribar M., Enczmann J., et al. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011, 117:98-107.
30. Cooper M.A., Elliott J.M., Keyel P.A., et al. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA 2009, 106:1915-1919.
31. Romee R., Schneider S.E., Leong J.W., et al. Cytokine activation induces human memory-like NK cells. Blood 2012, 120:4751-4760.
32. Eissens D.N., Van Der Meer A., Van Cranenbroek B., et al. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant 2010, 10:1981-1990.
33. Derniame S., Perazzo J., Lee F., et al. Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2. Cytotherapy 2014, 0:1-10.
34. Vey N., Bourhis J.-H., Boissel N., et al. Aphase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012, 120:4317-4323.
35. Benson D.M., Hofmeister C.C., Padmanabhan S., et al. A phase I trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012, 120:4324-4333.
36. Romagné F., André P., Spee P., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
37. Savani B.N., Mielke S., Adams S., et al. Rapid killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007, 21:2145-2152.